Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Group 1 - Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases [4] - The company will present updated clinical data on its investigational therapy rese-cel at two upcoming scientific meetings in February 2025 [1][2] - Rese-cel is designed to transiently and completely deplete all CD19-positive cells, potentially resetting the immune system for patients with autoimmune diseases [3] Group 2 - The RESET™ clinical development program includes multiple disease-specific trials across various therapeutic areas such as rheumatology, neurology, and dermatology [3][4] - The lead strategy of Cabaletta Bio, CARTA, aims to advance engineered T cell therapies for autoimmune diseases [4] - Presentations at the scientific meetings will cover safety, translational data, and clinical outcomes from the first 10 patients dosed with rese-cel [1][2]